Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting
出版年份 2021 全文链接
标题
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-12-22
DOI
10.3389/fimmu.2021.802858
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Age‐dependent and gender‐dependent antibody responses against SARS‐CoV ‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine
- (2021) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
- (2021) Ane Ogbe et al. Nature Communications
- SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients
- (2021) Yao Deng et al. Cellular & Molecular Immunology
- COVID-19 vaccines
- (2021) Duduzile Ndwandwe et al. CURRENT OPINION IN IMMUNOLOGY
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
- (2021) Alejandro Jara et al. NEW ENGLAND JOURNAL OF MEDICINE
- BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
- (2021) Yaniv Lustig et al. Lancet Respiratory Medicine
- Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
- (2021) Rebecca P. Payne et al. CELL
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
- (2020) Hui Wang et al. CELL
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
- (2020) Julian Braun et al. NATURE
- Divergent SARS‐CoV‐2‐specific T and B cell responses in severe but not mild COVID‐19 patients
- (2020) Anna E. Oja et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- The lightning-fast quest for COVID vaccines — and what it means for other diseases
- (2020) Philip Ball NATURE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment
- (2018) Qin Wang et al. Frontiers in Immunology
- TLR1/2 Ligand-Stimulated Mouse Liver Endothelial Cells Secrete IL-12 and Trigger CD8+ T Cell Immunity In Vitro
- (2013) J. Liu et al. JOURNAL OF IMMUNOLOGY
- The Xs and Y of immune responses to viral vaccines
- (2010) Sabra L Klein et al. LANCET INFECTIOUS DISEASES
- Sexual dimorphism of humoral immunity with human vaccines
- (2008) Ian Francis Cook VACCINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started